VIVEbiotech

VIVEbiotech is a specialized lentiviral vector CDMO that has rapidly become a key enabler for advanced therapy developers worldwide. With deep virology expertise, over a decade of operational history, and a pure-play focus on lentivirus, the company offers tailored process development and GMP manufacturing services from its dedicated cleanrooms in Spain. A significant growth investment from Ampersand Capital Partners in 2024 is fueling an expansion of its capabilities to meet rising demand, positioning it as a critical infrastructure partner in the burgeoning cell and gene therapy sector.

Specialized platform for the development and GMP manufacturing of lentiviral vectors for ex vivo and in vivo cell and gene therapy applications, with expertise in virology, process optimization, and scalable bioreactor production.

VIVEbiotech competes with large, diversified CDMOs (e.g., Lonza, Catalent, Thermo Fisher) that have lentiviral vector offerings, as well as other specialized viral vector CDMOs. Its key competitive advantages are its exclusive focus on lentivirus, deep virology expertise, and proven regulatory track record, allowing it to compete on quality and specialization rather than scale alone.